"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead

Case report

Diagnosis of Stroke on Neuroimaging of COVID-19 Patients in Coma: A Case Series


Patients with severe coronavirus disease 2019 (COVID-19) disease suffer from many thrombotic complications including deep vein thrombosis, pulmonary embolism, myocardial infarction (MI), and stroke. Large vessel strokes have been reported in young patients with COVID-19 disease. We report four cases of stroke diagnosed based on CT scan in critically ill individuals treated in the medical intensive care unit in a health facility in New York. All patients were receiving supportive treatment and mechanical ventilation at the time of diagnosis. All patients had impaired consciousness and were unable to wake up after sedation had worn off, prompting further workup. The pathogenesis of stroke could be secondary to the embolic phenomenon vs. hypercoagulopathy in our patients. Stroke should be considered in all COVID-19 patients who present with altered mental status. Severe COVID-19 patients with risk factors of stroke may benefit from therapeutic anticoagulation.


Coronavirus disease 2019 (COVID-19) infection can lead to many complications including deep vein thrombosis, pulmonary embolism, myocardial infarction (MI), and stroke. The exact pathogenesis of these thrombotic complications is not known. We report four cases of stroke presenting as coma who were treated in a health facility in New York over a three-week period between March 30, 2020, through April 17, 2020, while they were undergoing treatment in the medical intensive care unit. All four patients in this series had a positive nasopharyngeal swab for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); they had radiographic evidence of viral pneumonia on CT imaging and were diagnosed with severe COVID-19 disease.

Case Presentation

Clinical characteristics, risk factors, laboratory and imaging data, and outcomes of all patients are presented in Table 1.

Variable Patient 1 Patient 2 Patient 3 Patient 4
Age (years) 41 67 71 67
Sex Female Male Female Female
Medical history and risk factors for stroke 22 weeks gestation, DIC/IUFD Type 2 diabetes mellitus, hyperlipidemia, atrial flutter Osteoarthritis of hip Type 2 diabetes mellitus, hyperlipidemia
Home medications None Home medications unavailable None Amlodipine, metoprolol, atorvastatin, glimepiride, sitagliptin
COVID-19 symptoms Cough, fever for 7 days Cough, fever, diarrhea, SOB for 10 days SOB, fever for 10 days Fever, cough for 7 days, SOB for 2 days
Admission-stroke onset (days) 4 18 18 6
Signs and symptoms of stroke Altered mental status, inability to wake up off sedation for 36 hours Altered mental status, inability to wake up off sedation for 42 hours Altered mental status, inability to wake up off sedation for 36 hours Altered mental status, inability to wake up off sedation for 48 hours
GCS score after sedation t 1/2 elimination* 3/15 3/15 3/15 3/15
NIHSS score Not available; patient intubated and sedated Not available; patient intubated and sedated Not available; patient intubated and sedated Not available; patient intubated and sedated
Vascular territory (CT head) Right and left middle cerebral artery Bilateral cerebral hemispheres and left inferior cerebellum. Superimposed foci of intraparenchymal and/or extra-axial acute hemorrhages within the right frontoparietal regions Left posterior cerebral artery infarct and small infarct in the left splenium of the corpus callosum Multifocal infarcts in supratentorial and infratentorial compartments and anterior cerebral artery
CTA No large vessel occlusion No large vessel occlusion Occlusion of proximal left PCA. Moderate-severe stenosis of P2 right PCA Not done
Carotid Doppler 4-5 mm right ICA aneurysm No stenosis/thrombus at CCA bifurcation No stenosis/thrombus at CCA bifurcation Not done
MRA Not done Not done Not done Not done
INR 1.07 1.13 1.1 1.1
PTT, seconds (25-32) 24.5 28.6 29.8 21
D-dimer, mg/L (<0.59) >35 >35 20.8 >35
WBC, k/mm(4.8-10.8) 37.5 19.5 6.4 24.2
Neutrophils, % (32-70) 93 92.1 60 86
Lymphocytes, % (21-55) 2 1.4 16.6 5
Platelets, k/mm3 (160-410) 71 52 274 336
LDH, U/L (125-220) 2,360 1,292 281 618
Haptoglobin (13-281) <8 Not done Not done Not done
Schistocytes Occasional None None Occasional
Troponin, ng/ml (0.00-0.02) <0.02 0.02 0.03 0.05
BNP, pg/ml (<100) 467 289 44 67
APLA workup, protein C, S Negative Negative Negative Negative
CRP, mg/dl (0.00-0.50) 1.2 4.6 2.8 7.0
Ferritin, ug/L (18-370) 1,429 2,627 5,454 3,583
Procalcitonin, ng/ml (0.15-2) 7 1.01 0.07 2.5
Renal failure Yes Yes Yes Yes
Hemodialysis CVVHD transitioned to HD and not requiring HD at discharge HD during the hospital stay; not requiring HD at discharge AKI self-resolved; did not require HD RRT not initiated; was made DNR and started palliative care as per HCP wishes
MI No No No No
TTE EF: 60-65%; no PFO/endocarditis/septal effects/thrombus EF: 50-55%; no PFO/endocarditis/septal effects/thrombus EF: 60-65%; no PFO/endocarditis/septal effects/thrombus EF: 45-50%; no PFO/endocarditis/septal effects/thrombus
Arrhythmia None SVT, A-fib during the hospital stay. Also had baseline A.flutter None None
Treatment for stroke Aspirin, statin Aspirin, statin Aspirin, statin Aspirin, statin
Treatment for COVID-19 Azithromycin, hydroxychloroquine, tocilizumab, pulse dose steroids, plasma Tocilizumab, azithromycin, hydroxychloroquine, pulse dose steroids, plasma Azithromycin, hydroxychloroquine, pulse dose steroids Azithromycin, hydroxychloroquine, pulse dose steroids
Anticoagulation (uninterrupted) Heparin drip therapeutic with PTT goal of 50-60 Heparin prophylactic 5,000 u SC Q8H Heparin prophylactic 5,000 u SC Q8H Heparin prophylactic 5,000 u SC Q8H
Outcome status Tracheostomy done, discharged to subacute rehab Tracheostomy done, discharged to subacute rehab Tracheostomy done, discharged to long-term acute rehab Deceased

Imaging results of all patients are illustrated below (Figure 1, Figure 2, Figure 3, Figure 4).

Two of the four patients had known risk factors for stroke. Patient number one was pregnant and was diagnosed with having intrauterine fetal death (IUFD) at 22 weeks gestation and subsequently noted to have disseminated intravascular coagulation (DIC). Patient number two had h/o atrial flutter at admission. He also developed supraventricular tachycardia (SVT) and A-fib during his ICU stay. None of them had patent foramen ovale (PFO)/septal defects/intracardiac thrombus on transthoracic echocardiogram (TTE). All patients had negative blood cultures during their hospital stay. All patients had renal failures at some point during the ICU stay. No patient had a history of transient ischaemic attack (TIA), stroke, or prior coagulopathy. No patients had MI during the ICU stay. Hypercoagulopathy workup done in all the patients was negative for antiphospholipid antibody syndrome and protein C/protein S deficiency.

The symptoms of stroke noted in these patients were altered mental status and the inability to wake up once sedation wore off. All patients were receiving mechanical ventilation at the time of stroke diagnosis. The interval between the onset of symptoms of COVID-19 and the diagnosis of stroke ranged from seven to 27 days. The interval between intubation and diagnosis of stroke ranged from zero to 17 days.

All four patients had an ischemic stroke on CT imaging. Two of those had hemorrhagic conversion (patients 2 and 3), and hence they were not treated with therapeutic anticoagulation after the diagnosis of stroke. Patient 4 had extensive involvement with multiple territories and did not receive therapeutic anticoagulation. Hence, only patient 1 was treated with therapeutic anticoagulation with heparin drip after the diagnosis of stroke. All patients were on prophylactic heparin subcutaneously during their hospital stay (i.e., all patients were found to have stroke despite prophylactic anticoagulation.) None of our patients were treated with tissue plasminogen activator (TPA)/endovascular therapy. Patients 2 and 3 had a hemorrhagic conversion, and patient 4 had extensive multifocal infarcts. Also, the exact onset of stroke was not known in any of our patients.

Even though all our patients had altered mental status, renal failure, and coagulopathy, none of them fit the criteria of thrombotic thrombocytopenic purpura (TTP) as none of them had microangiopathic hemolytic anemia. Hence all the above-mentioned conditions were thought to be secondary to COVID-19 rather than TTP.

All patients received azithromycin, hydroxychloroquine, and high-dose Solu-Medrol® 1 g/day (Pfizer, Brooklyn, NY). Patients 1 and 2 received tocilizumab and plasma in addition to other COVID-19 treatment.


It has been noted that the number of diagnosed cases of stroke in many countries has declined coinciding with the declaration of community spread of novel coronavirus. This is attributed to more people staying at home out of fear of contracting coronavirus [1]. However, several studies have reported a possible association between SARS-CoV-2 infection and an increased risk of stroke [2]. The incidence of thrombotic complications in ICU patients with COVID-19 infections was found to be 31% in a study [3]. Prior studies indicate that a very small proportion (5%) of COVID-19 patients requiring hospitalization are diagnosed with stroke [2-4]. Large vessel thrombotic strokes were reported in young individuals [5]. Some of them do not have classical signs or symptoms of stroke or present with altered mental status and are unable to communicate, making the diagnosis of stroke a challenge. The median time from admission to stroke diagnosis was 12 days in our study compared to 21 days in another study [6].

The pathogenesis of stroke in COVID-19 infection is not clearly understood. Multiple mechanisms have been proposed including hypoxic injury, direct injury, immune injury, endothelial injury, embolism, DIC, necrotizing encephalopathy, vasculitis, and cardiomyopathy and activation of the coagulation pathway, with the latter being the more likely reason [7].

Activation of the coagulation pathway occurs early in the disease process and this leads to excessive production of proinflammatory cytokines believed to be responsible for multiorgan injuries. Imbalance of procoagulant-anticoagulant activity due to excessive inflammation is the proposed mechanism behind micro-thrombosis and DIC leading to thrombotic complications including pulmonary embolism and stroke. High D-dimer levels, often twice above the normal range, are noticed, reflecting the prothrombotic stage, and high D-dimer levels have been correlated with severe disease, worse prognosis, and higher mortality [8,9]. Studies have demonstrated that COVID-19 patients with stroke had high levels of D-dimer and C-reactive protein (CRP) than COVID-19 patients without stroke [10]. Our study included only patients with stroke and they all had high CRP and D-dimer at the time of the diagnosis of stroke. The acute inflammation caused by COVID-19 is probably prone to a hypercoagulable state that could lead to stroke.

In our series, multi-territorial infarctions were noted in all patients, suggesting arterial embolism, although large vessel occlusion has also been noted in patients with COVID-19 with or without traditional risk factors [11]. Hemorrhagic stroke is less common in COVID-19 [12]. Hence, one can debate about the pathogenesis of embolism vs. hypercoagulability regarding the cause of stroke in these patients. It seems likely that anticoagulation will play a substantial role in the management of stroke in COVID-19.

Angiotensin-converting enzyme 2 (ACE2) has been identified as a co-receptor for SARS-CoV-2 entry into cells, and it is expressed in many organs including the central nervous system (CNS). Neurotropism has been identified in coronaviruses causing SARS and the Middle East respiratory syndrome (MERS), and similarly, SARS-CoV-2 may invade the CNS through hematogenous spread or from peripheral nerve terminals and cause various neurologic manifestations [2,4]. Our patients were intubated and sedated, but as some studies have reported anosmia as a symptom of SARS-COV-2 infection, it supports the hypothesis of the invasion of the virus through the retrograde neuronal route.

The relationship between pneumonia and increased thrombosis is well established, but no clear mechanism has been established. In one study, critically ill H1N1 patients with acute respiratory distress syndrome (ARDS) were noted to have 17.9 times increased risk of venous thromboembolism (VTE) [13]. Elevated stroke risk in infections is likely due to the activation of clotting cascade by inflammation [14].

A comparison of our case series with other published studies regarding stroke in COVID-19 is presented in Table 2.

Study Type of study Diagnostic modality Finding Mean age of the study population (years)
Current study Retrospective CT Acute cerebrovascular disease 61.5
Helms et al., 2020, France [4] Prospective MRI Cerebral ischemic stroke 63
Klok et al., 2020, Netherlands [3] Prospective CT Acute cerebrovascular disease 64
Li et al., 2020, China [10] Retrospective CT Acute cerebrovascular disease 53.3
Lodigiani et al., 2020, Italy [15] Retrospective Report of treating physician Acute cerebrovascular disease 66
Lu et al., 2020, China [16] Retrospective Not reported Acute cerebrovascular disease 44
Mao et al., 2020, China [2] Retrospective CT Acute cerebrovascular disease 52.7

All patients were intubated and sedated during the study; hence, consent was obtained from the HCP of all patients for the data collection and publication of this case report.


Any patient with stroke or stroke-like symptoms should be screened for co-existing SARS-CoV-2 infection during this COVID-19 pandemic. Stroke patients are susceptible to severe COVID-19 infections and they usually have a worse prognosis. Critically ill patients with COVID-19 infection are at higher risk of developing stroke. Stroke should be considered in all patients presenting with altered mental status in the setting of COVID-19 infection. In patients with high D-dimer levels and those who also have traditional risk factors of stroke and acceptable bleeding risk, therapeutic anticoagulation may be considered.


  1. Markus HS, Brainin M: COVID-19 and stroke-a global World Stroke Organization perspective. Int J Stroke. 2020, 15:361-364. 10.1177/1747493020923472
  2. Mao L, Jin H, Wang M, et al.: Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020, 77:683-690. 10.1001/jamaneurol.2020.1127
  3. Klok FA, Kruip MJHA, van der Meer NJM, et al.: Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020, 191:145-147. 10.1016/j.thromres.2020.04.013
  4. Helms J, Kremer S, Merdji H, et al.: Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020, 382:2268-2270. 10.1056/NEJMc2008597
  5. Oxley TJ, Mocco J, Majidi S, et al.: Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020, 382:e60. 10.1056/NEJMc2009787
  6. Rothstein A, Oldridge O, Schwennesen H, Do D, Cucchiara BL: Acute cerebrovascular events in hospitalized COVID-19 patients. Stroke. 2020, 51:e219-e222. 10.1161/STROKEAHA.120.030995
  7. Spence JD, de Freitas GR, Pettigrew LC, et al.: Mechanisms of stroke in COVID-19. Cerebrovasc Dis. 2020, 49:451-458. 10.1159/000509581
  8. Jose RJ, Manuel A: COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020, 8:e46-e47. 10.1016/S2213-2600(20)30216-2
  9. Zhou F, Yu T, Du R, et al.: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395:1054-1062. 10.1016/S0140-6736(20)30566-3
  10. Li Y, Li M, Wang M, et al.: Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol. 2020, 5:279-284. 10.1136/svn-2020-000431
  11. Grau AJ, Buggle F, Becher H, et al.: Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies. Neurology. 1998, 50:196-203. 10.1212/wnl.50.1.196
  12. Bhatia R, Pedapati R, Komakula S, Srivastava MVP, Vishnubhatla S, Khurana D: Stroke in coronavirus disease 2019: a systematic review. J Stroke. 2020, 22:324-335. 10.5853/jos.2020.02264
  13. Obi AT, Tignanelli CJ, Jacobs BN, et al.: Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. J Vasc Surg Venous Lymphat Disord. 2019, 7:317-324. 10.1016/j.jvsv.2018.08.010
  14. Macko RF, Ameriso SF, Gruber A, et al.: Impairments of the protein C system and fibrinolysis in infection-associated stroke. Stroke. 1996, 27:2005-2011. 10.1161/01.str.27.11.2005
  15. Lodigiani C, Iapichino G, Carenzo L, et al.: Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020, 191:9-14. 10.1016/j.thromres.2020.04.024
  16. Lu L, Xiong W, Liu D, et al.: New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: a retrospective multicenter study. Epilepsia. 2020, 61:e49-e53. 10.1111/epi.16524

Case report

Diagnosis of Stroke on Neuroimaging of COVID-19 Patients in Coma: A Case Series

Author Information

Rathnamitreyee Vegunta Corresponding Author

Internal Medicine, Westchester Medical Center, Valhalla, USA

Radhakrishna Vegunta

Oncology, University of North Dakota, Fargo, USA

Venkata R. Rokkam

Inpatient Medicine, Banner University Medical Center, University of Arizona, Tucson, USA

Gurusaravanan Kutti Sridharan

Internal Medicine, Banner University Medical Center, University of Arizona, Tucson, USA

Internal Medicine, University of Arizona, Tucson, USA

Ethics Statement and Conflict of Interest Disclosures

Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Case report

Diagnosis of Stroke on Neuroimaging of COVID-19 Patients in Coma: A Case Series

Figures etc.


Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Learn more here.